Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) granted inducement restricted stock units totaling 349,000 shares to three new employees on February 2, 2026, under the company's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest in four equal annual installments beginning on the first anniversary of the vesting commencement date, subject to continued service through each vesting date.

News Market Reaction

+4.54%

2 alerts

+4.54% News Effect

+$56M Valuation Impact

$1.29B Market Cap

0.0x Rel. Volume

On the day this news was published, TSHA gained 4.54%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $56M to the company's valuation, bringing the market cap to $1.29B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

RSU grant size: 349,000 shares Vesting schedule: 4 years Nasdaq rule: Rule 5635(c)(4)

3 metrics

RSU grant size 349,000 shares Aggregate RSUs granted to three new employees under 2023 Inducement Plan

Vesting schedule 4 years RSUs vest in four equal annual installments

Nasdaq rule Rule 5635(c)(4) RSU grants made as inducement awards under Nasdaq listing rules

Market Reality Check

Price: $4.49 Vol: Volume 3,901,148 is above...

normal vol

$4.49 Last Close

Volume Volume 3,901,148 is above the 20-day average of 2,639,586 (relative volume 1.48x). normal

Technical Price $4.41 is trading above the 200-day MA of $3.62 and 26.74% below the 52-week high of $6.02.

Peers on Argus

TSHA was down 2.86% while peers were mixed: gene therapy names like QURE and SAN...

TSHA was down 2.86% while peers were mixed: gene therapy names like QURE and SANA declined (-7.75%, -11.25%), while others like OCS and EYPT gained (4.33%, 2.74%). This points to a stock-specific move around today’s RSU grant.

Historical Context

5 past events · Latest: Jan 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 06	Rett program update	Positive	+7.6%	Progress on TSHA-102 pivotal REVEAL trial dosing and FDA alignment.
Dec 05	Inducement option grant	Neutral	+7.9%	Inducement stock options to new employees under 2023 Inducement Plan.
Nov 04	Q3 2025 earnings	Positive	-4.3%	Breakthrough Therapy designation, pivotal plan, and cash runway into 2028.
Oct 28	Earnings call notice	Neutral	+2.3%	Announcement of Q3 2025 results release and conference call schedule.
Oct 16	Rights regained	Positive	-4.9%	Company regained full global rights to TSHA-102 Rett program.

Pattern Detected

Recent news skewed positive (Rett program progress, regained rights, cash runway), yet price reactions have been mixed, with some clinically and strategically positive updates followed by negative moves while routine items and prior inducement grants sometimes saw gains.

Recent Company History

Over the past few months, Taysha has focused on its TSHA-102 Rett syndrome program and corporate housekeeping. On Oct 16, 2025, it regained full global rights to TSHA-102. Subsequent updates on pivotal trial progress and FDA alignment, including dosing the first REVEAL patient and plans for interim analyses, underscored clinical momentum. Financial results on Nov 4, 2025 highlighted cash of $297.3M with runway into 2028. Routine items such as conference-call notices and prior inducement equity grants also appeared, showing a pattern of steady operational activity alongside major clinical milestones.

Market Pulse Summary

This announcement details an inducement grant of 349,000 RSU-based shares to three new employees und...

Analysis

This announcement details an inducement grant of 349,000 RSU-based shares to three new employees under Nasdaq Rule 5635(c)(4), vesting over four years. It adds to a stream of operational updates following recent Rett syndrome trial progress and financial disclosures. Investors may monitor how ongoing equity-based compensation, insider trading filings, and future program milestones intersect with TSHA’s position above its 200-day MA yet still below its 52-week high.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), adeno-associated virus, +4 more

8 terms

restricted stock units financial

"granted three new employees, in the aggregate, restricted stock units (RSUs) representing 349,000 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"The RSUs will vest in four equal annual installments beginning on the first anniversary"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

adeno-associated virus medical

"focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases"

Adeno-associated virus (AAV) is a naturally occurring, small virus that researchers use as a safe carrier to deliver corrective genes into human cells, much like a specialized delivery van transporting instructions to a malfunctioning machine. It matters to investors because AAV-based therapies drive large development costs, unique manufacturing and regulatory risks, and the potential for high-value, one-time treatments that can significantly affect a biotech company’s future revenue and valuation.

aav medical

"advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases"

AAV is a small, generally harmless virus repurposed by researchers as a delivery vehicle to insert therapeutic genes into human cells; think of it as a postal service that carries corrective DNA to specific tissues. Investors pay attention because AAV-based treatments can offer durable, potentially one-time cures that command high prices, but they also carry development, manufacturing and regulatory risks that can sharply influence a biotech company’s value.

monogenic medical

"gene therapies for severe monogenic diseases of the central nervous system (CNS)"

Monogenic describes a disease or trait caused by a change in a single gene. Think of it like a single broken circuit in a complex machine: fixing or detecting that one fault can be straightforward compared with problems caused by many parts. For investors, monogenic conditions often mean clearer diagnostic tests, more targeted drug strategies and potentially faster clinical development or regulatory paths, which can affect investment risk and potential returns.

central nervous system medical

"gene therapies for severe monogenic diseases of the central nervous system (CNS)"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

cns medical

"diseases of the central nervous system (CNS), today announced that, on February 2, 2026"

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

AI-generated analysis. Not financial advice.

DALLAS, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on February 2, 2026, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, restricted stock units (RSUs) representing 349,000 shares of the Company’s common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date, subject to such employee's continued service with the Company through each such vesting date.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com

FAQ

What did Taysha (TSHA) announce on February 2, 2026 about employee equity?

Taysha granted inducement RSUs totaling 349,000 shares to three new employees. According to the company, the awards were made under the 2023 Inducement Plan and follow Nasdaq Listing Rule 5635(c)(4) as part of hiring arrangements.

How do the RSUs granted by Taysha (TSHA) vest and when does vesting start?

The RSUs vest in four equal annual installments starting on the first anniversary of the vesting commencement date. According to the company, vesting is conditioned on each employee's continued service through each annual vesting date.

Why did Taysha (TSHA) use an inducement grant under Nasdaq Listing Rule 5635(c)(4)?

The inducement grant was used to provide equity as a material hiring incentive for new employees. According to the company, the awards comply with Nasdaq Listing Rule 5635(c)(4) permitting certain equity grants tied to new employment.

How many employees and how many shares were included in Taysha's (TSHA) inducement grant?

Three new employees received inducement awards aggregating 349,000 restricted stock units. According to the company, the RSUs were granted in connection with those individuals entering employment with Taysha.

Could Taysha's (TSHA) 349,000 RSUs materially affect existing shareholders?

The announcement does not state a percentage dilution impact, so materiality is unclear from the disclosure alone. According to the company, the grants are standard inducement awards; investors should compare the share count to outstanding shares to assess dilution.